Increased allelic loss in toluidine blue-positive oral premalignant lesions

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 95, Issue 1, 2003, Pages 45-50

  Epstein, Joel B ^a,b,c,d   Zhang, Lewei ^a,c   Poh, Catherine ^a   Nakamura, Hisae ^e   Berean, Ken ^b,c   Rosin, Miriam ^b,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA; TOLONIUM CHLORIDE; COLORING AGENT; DIAGNOSTIC AGENT;

ADULT; AGED; ALLELISM; ARTICLE; CANCER RISK; CHROMOSOME 3; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; GENE LOCUS; HETEROZYGOSITY; HUMAN; HYPERPLASIA; LEUKOPLAKIA; MALE; MOUTH CARCINOMA; SAMPLING; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; CHI SQUARE DISTRIBUTION; CHROMOSOME 17; CHROMOSOME 9; CHROMOSOME DELETION; CLINICAL TRIAL; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; MOUTH TUMOR; PRECANCER; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 9; COLORING AGENTS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPLASIA; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS; TOLONIUM CHLORIDE;

EID: 0038521470     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2003.97     Document Type: Article

References (20)

1. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997;89:199-211.
2. Khuri FR, Kim E, Lee J, Winn R, Benner S, Lippman S, et al. Cancer Epidemiol Biomarkers Prev 2001;10:823-9.
3. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001;49:72-82.
4. Shah JP. Head and neck surgery. 2nd ed. London: Mosby-Wolfe; 1996. pp. 189-196.
5. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73:187-90.
6. Rosenberg D, Cretin S. Use of meta-analysis to evaluate tolonium chloride in oral cancer screening. J Oral Surg 1989;67:621-7.
7. Mashberg A. Tolonium (Toluidine Blue) rinse - a screening method for recognition of squamous carcinoma. JAMA 1981;245:2408-10.
8. Pizer ME, Dubois DD. An assessment of toluidine blue for the diagnosis of lip lesions. VA Med 1979;106:860-2.
9. Epstein JB, Oakley C, Millner A, Emerton S, van der Meij E, Le N. The utility of toluidine blue application as a diagnostic aid in patients previously treated for upper aerodigestive tract cancers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:537-47.
10. Warnakulasuriya KAAS, Johnson NW. Sensitivity and specificity of Orascan Toluidine Blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med 1996;5:97-103.
11. Califano J, Van Der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
12. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
13. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-62.
14. Partridge M, Pateromichelakis S, Phillips E, EMILION GG, A'hern RP, Langdon JD. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000;60:3893-8.
15. Zhang L, Rosin MP. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? [review]. J Oral Pathol Med 2001;30:513-20.
16. Zhang L, Michelsen C, Cheng X, Zeng T, Priddy R, Rosin MP. Molecular analysis of oral lichen planus: is this a premalignant lesion. Am J Pathol 1997;151: 323-7.
17. Poh CF, Zhang L, Lam WL, Zhang X, An D, Chau C, et al. A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Invest 2001;81:629-34.
18. Zhang L, Cheung K-J, Lam WL, Cheng X, Poh C, Priddy R, et al. Increased genetic damage in oral leukoplakia from high-risk sites: potential impact on staging and clinical management. Cancer 2001;91:2148-55.
19. Zhang L, Poh CF, Lam WL, Epstein JB, Cheng X, Zhang X, et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 2001;37:505-12.
20. Guo Z, Yamaguchi K, Sanchez-Cespedes M, Westra WH, Koch WM, Sidransky D. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancies. Clin Cancer Res 2001;7:1963-8.